These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11219309)

  • 1. Update on cross-resistance of fluoroquinolones.
    Garau J
    Int J Clin Pract Suppl; 2000 Dec; (115):94-8. PubMed ID: 11219309
    [No Abstract]   [Full Text] [Related]  

  • 2. [Where are quinolones going? New agents in development].
    Holzgrabe U
    Pharm Unserer Zeit; 2001; 30(5):446-8. PubMed ID: 11575182
    [No Abstract]   [Full Text] [Related]  

  • 3. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of action and resistance to fluoroquinolones].
    Alarcón T; López-Brea M
    Enferm Infecc Microbiol Clin; 1996 Feb; 14(2):111-7. PubMed ID: 8714159
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
    Ruiz J
    J Antimicrob Chemother; 2003 May; 51(5):1109-17. PubMed ID: 12697644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone resistance: mechanisms and epidemiology.
    Tillotson GS; Dorrian I; Blondeau J
    J Med Microbiol; 1997 Jun; 46(6):457-61. PubMed ID: 9379475
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quinolones. Gyrase inhibitors].
    Höffler D
    Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
    [No Abstract]   [Full Text] [Related]  

  • 9. [New quinolones, current therapies].
    Auckenthaler R
    Schweiz Rundsch Med Prax; 1988 Nov; 77(45):1217-8. PubMed ID: 2847274
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of new quinolones: the inhibitory activity on DNA gyrase.
    Sato K; Hoshino K; Mitsuhashi S
    Prog Drug Res; 1992; 38():121-32. PubMed ID: 1319080
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
    Inagaki H; Takahashi H; Takemura M
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5193-8. PubMed ID: 15380226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of drug inhibition of DNA gyrase.
    Lewis RJ; Tsai FT; Wigley DB
    Bioessays; 1996 Aug; 18(8):661-71. PubMed ID: 8760340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent development in quinolone compounds antitumor quinolones].
    Yang YS; Zhao SR; Ji RY; Chen KX
    Yao Xue Xue Bao; 1998; 33(2):157-60. PubMed ID: 11938953
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of quinolone action and microbial response.
    Hawkey PM
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():29-35. PubMed ID: 12702701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How are quinolones used in clinical practice? Gyrase antagonists from the viewpoint of the hospital pharmacist].
    Schurz JK
    Pharm Unserer Zeit; 2001; 30(5):400-5. PubMed ID: 11575176
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa].
    Shen JL; Zhu DM; Wang MG
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1859-62. PubMed ID: 19040025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R; Garrigues TM; Cantón E
    Rev Esp Quimioter; 2002 Mar; 15(1):25-31. PubMed ID: 12582434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis.
    Cholongitas E; Papatheodoridis GV; Lahanas A; Xanthaki A; Kontou-Kastellanou C; Archimandritis AJ
    Liver Int; 2005 Feb; 25(1):57-61. PubMed ID: 15698399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.